{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:35:27Z","timestamp":1766586927009,"version":"3.48.0"},"reference-count":97,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Transplant patients experience high morbidity and mortality caused by respiratory viral infections (RVIs). In the past decade, numerous methods of prophylaxis and treatment have rapidly developed and continue to expand, with dozens of novel agents in preclinical and clinical trials. This includes recent scientific breakthroughs in virus structure, which have enabled the creation of respiratory syncytial virus (RSV) vaccines. While new vaccines, antivirals, monoclonal antibodies, and non-vaccine agents are becoming more available, their utility and safety in the transplant populations are often uncertain. This review summarizes the current landscape of RVIs in the transplant population, including approaches to pre- and post-exposure prophylaxis and treatment. We discuss the data behind vaccine timing, safety, and efficacy and current pre- and post-transplant recommendations, with a particular focus on influenza, SARS-CoV-2, and RSV. We also examine the potential benefits of antivirals, monoclonal antibodies, and novel agents used as prophylaxis, treatment, or adjuncts. While there remain many knowledge gaps, these new methods and ongoing advancements in RVI treatment and prevention promise to improve transplant patient outcomes.<\/jats:p>","DOI":"10.3390\/v18010008","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:27:51Z","timestamp":1766586471000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4694-2005","authenticated-orcid":false,"given":"Adriana A. M.","family":"Giuliani","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA"},{"name":"Division of Infectious Diseases, Rady Children\u2019s Hospital, San Diego, CA 92123, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California San Diego Health, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-2691","authenticated-orcid":false,"given":"Nancy","family":"Law","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/ajt.16383","article-title":"Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: A nationwide, multi-season prospective cohort study","volume":"21","author":"Mombelli","year":"2021","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41409-024-02304-4","article-title":"Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease","volume":"59","author":"Montoro","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13511","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nofzinger, T.B., Huang, T.T., Lingat, C.E.R., Amonkar, G.M., Edwards, E.E., Yu, A., Smith, A.D., Gayed, N., and Gaddey, H. (2025). Vaccine fatigue and influenza vaccination trends across Pre-, Peri-, and Post-COVID-19 periods in the United States using epic\u2019s cosmos database. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0326098"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-virology-012420-022445","article-title":"Seasonality of Respiratory Viral Infections","volume":"7","author":"Moriyama","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1038\/s41598-023-31057-1","article-title":"Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe","volume":"13","author":"Wiemken","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_7","unstructured":"Giuliani, A. (2025, December 10). Created in BioRender. Available online: https:\/\/BioRender.com\/cu1xygq."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/ciy294","article-title":"A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients","volume":"67","author":"Kumar","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_9","unstructured":"Federal Drug Administration (2025). Influenza Vaccine Composition for the 2025\u20132026 U.S. Influenza Season."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2347019","DOI":"10.1080\/21645515.2024.2347019","article-title":"Pandemic preparedness through vaccine development for avian influenza viruses","volume":"20","author":"Faccin","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Kumar","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Silva-Pinto, A., Abreu, I., Martins, A., Bastos, J., Ara\u00fajo, J., and Pinto, R. (2024). Vaccination After Haematopoietic Stem Cell Transplant: A Review of the Literature and Proposed Vaccination Protocol. Vaccines, 12.","DOI":"10.3390\/vaccines12121449"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/cid\/cix1081","article-title":"A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients","volume":"66","author":"Chong","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/cid\/ciw855","article-title":"Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1\u20132, a Randomized Controlled Clinical Trial","volume":"64","author":"Cordero","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/cid\/ciad477","article-title":"Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss\/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)","volume":"78","author":"Mombelli","year":"2024","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase Inhibitors for Influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40121-019-00271-8","article-title":"Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients","volume":"8","author":"Mitha","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Committee On Infectious Diseases (2022). Recommendations for Prevention and Control of Influenza in Children 2022\u20132023. Pediatrics, 150, e2022059275.","DOI":"10.1542\/peds.2022-059274"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): A randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e14249","DOI":"10.1111\/tid.14249","article-title":"Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients","volume":"26","author":"Ringer","year":"2024","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"(2025, September 30). Cidara Therapeutics Announces Positive Topline Results from Its Phase 2b Navigate Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza (2025). Cidara Therepeutics. Available online: https:\/\/www.cidara.com\/news\/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70100","DOI":"10.1111\/ctr.70100","article-title":"Clinical Practice Recommendations on the Effect of COVID-19 Vaccination Strategies on Outcomes in Solid Organ Transplant Recipients","volume":"39","author":"Foroutan","year":"2025","journal-title":"Clin. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtct.2022.10.010","article-title":"Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology","volume":"29","author":"Khawaja","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/TP.0000000000004151","article-title":"The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic","volume":"106","author":"Nimmo","year":"2022","journal-title":"Transplantation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e13998","DOI":"10.1111\/tid.13998","article-title":"Difference between SARS-CoV-2, seasonal coronavirus, influenza, and respiratory syncytial virus infection in solid organ transplant recipients","volume":"25","author":"Mendoza","year":"2023","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.ajt.2024.03.011","article-title":"Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023","volume":"24","author":"Solera","year":"2024","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_29","first-page":"4612","article-title":"Effectiveness of 2024\u20132025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes\u2014IVY Network 2025, 26 Hospitals, September 1, 2024-April 30, 2025","volume":"33","author":"Ma","year":"2025","journal-title":"medRxiv Prepr. Serv. Health Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alshukairi, A.N., Al-Qahtani, A.A., Obeid, D.A., Dada, A., Almaghrabi, R.S., Al-Abdulkareem, M.A., Alahideb, B.M., Alsanea, M.S., Alsuwairi, F.A., and Alhamlan, F.S. (2023). Molecular Epidemiology of SARS-CoV-2 and Clinical Manifestations among Organ Transplant Recipients with COVID-19. Viruses, 16.","DOI":"10.3390\/v16010025"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1093\/infdis\/jiae140","article-title":"Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients","volume":"230","author":"Figueroa","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(22)00650-8","article-title":"Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): A randomised clinical trial","volume":"23","author":"Kho","year":"2023","journal-title":"Lancet. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.idc.2023.03.002","article-title":"COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence","volume":"37","author":"Vafea","year":"2023","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamainternmed.2021.7372","article-title":"Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial","volume":"182","author":"Heinzel","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Osmanodja, B., Ronicke, S., Budde, K., Jens, A., Hammett, C., Koch, N., Seelow, E., Waiser, J., Zukunft, B., and Bachmann, F. (2022). Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J. Clin. Med., 11.","DOI":"10.1101\/2022.03.23.22270017"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000004140","article-title":"A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients with Suboptimal Vaccine Response","volume":"106","author":"Karaba","year":"2022","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hamm, S.R., Loft, J.A., P\u00e9rez-Al\u00f3s, L., Heftdal, L.D., Hansen, C.B., M\u00f8ller, D.L., Pries-Heje, M.M., Hasselbalch, R.B., Fogh, K., and Hald, A. (2024). The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines. Viruses, 16.","DOI":"10.3390\/v16060860"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and Risk Factors Associated with Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.transproceed.2022.10.023","article-title":"The Trajectory of the COVID-19 Vaccine Antibody Titers Over Time and the Association of Mycophenolate Mofetil in Solid Organ Transplant Recipients","volume":"54","author":"Sakai","year":"2022","journal-title":"Transplant. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/TP.0000000000004177","article-title":"Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil-containing Immunosuppressive Regimens","volume":"106","author":"Berger","year":"2022","journal-title":"Transplantation"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Messchendorp, A.L., Zaeck, L.M., Bouwmans, P., van den Broek, D.A.J., Fr\u00f6lke, S.C., Geers, D., Imhof, C., Malahe, S.R.K., Schmitz, K.S., and Reinders, J. (2025). Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciaf107.","DOI":"10.1093\/cid\/ciaf107"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1111\/tid.70067","article-title":"Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients with Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity","volume":"27","author":"Ferreira","year":"2025","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_43","first-page":"9687","article-title":"mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients","volume":"30","author":"Albiol","year":"2022","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Falck-Ytter, Y., Kim, A.Y., Li, J.Z., Baden, L.R., Johnson, S., Shafer, R.W., Shoham, S., Tebas, P., and Bedimo, R. (2024). 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciae435.","DOI":"10.1093\/cid\/ciae435"},{"key":"ref_45","unstructured":"INVIVYD (2025, September 30). PEMGARDA Authorized for Emergency Use. Available online: https:\/\/pemgarda.com\/?gad_source=1&gad_campaignid=21506626247."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1093\/cid\/ciae510","article-title":"Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence from the Omicron-Dominant Era","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ajt.17199","article-title":"Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave","volume":"23","author":"Solera","year":"2023","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined with Nirmatrelvir\/Ritonavir in Patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): A placebo-controlled, randomised, double-blind, phase 2 trial","volume":"25","author":"Weinstein","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/ajt.17098","article-title":"Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge","volume":"22","author":"Radcliffe","year":"2022","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_51","first-page":"897","article-title":"Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: A 9-year retrospective multicentre study","volume":"27","author":"Testaert","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2500\/aap.2023.44.230030","article-title":"The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist\/immunologist","volume":"44","author":"Frenkel","year":"2023","journal-title":"Allergy Asthma Proc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Anastassopoulou, C., Medi\u0107, S., Ferous, S., Boufidou, F., and Tsakris, A. (2025). Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13020097"},{"key":"ref_55","unstructured":"(2025, September 30). MRESVIA\u2014Respiratory Syncytial Virus Vaccine Suspension (2025). DailyMed: Food and Drug Administration, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e5c837e7-41e8-496a-9c85-6b0453b35948."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ajt.2024.02.003","article-title":"The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation","volume":"24","author":"Trubin","year":"2024","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Almeida, N.C., Parameswaran, L., DeHaan, E.N., Wyper, H., Rahman, F., Jiang, Q., Li, W., Patton, M., Lino, M.M., and Majid-Mahomed, Z. (2025). Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults. Vaccines, 13.","DOI":"10.3390\/vaccines13030328"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e258322","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2533828","DOI":"10.1001\/jamanetworkopen.2025.33828","article-title":"Respiratory Syncytial Virus Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"8","author":"Redjoul","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ajt.2025.03.025","article-title":"Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees","volume":"25","author":"Havlin","year":"2025","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Hall, V.G., Alexander, A.A., Mavandadnejad, F., Kern-Smith, M., Dang, X., Kang, R., Humar, S., Winichakoon, P., Johnstone, R., and Aversa, M. (Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., 2025). Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., ahead of print. https:\/\/doi.org\/10.1016\/j.cmi.2025.09.013.","DOI":"10.1016\/j.cmi.2025.09.013"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/521912","article-title":"Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation","volume":"45","author":"Robin","year":"2007","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/10428194.2018.1468896","article-title":"Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab","volume":"60","author":"Permpalung","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","unstructured":"Ernst, D. (2025, September 30). RSV Prevention Therapy Palivizumab to Be Discontinued. MPR: Medical Professionals Reference. Available online: https:\/\/www.empr.com\/news\/rsv-prevention-therapy-palivizumab-to-be-discontinued\/#xd_co_f=MjU4NDVkMTItODAzZi00OWUzLTljZjUtNmQyMTNiNTdmMjc4~&quot;."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/cid\/ciab969","article-title":"Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies","volume":"74","author":"Lunter","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e13464","DOI":"10.1111\/tid.13464","article-title":"Ribavirin and cellular ribavirin-triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus","volume":"23","author":"Mueller","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/TP.0000000000002985","article-title":"Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients","volume":"104","author":"Permpalung","year":"2020","journal-title":"Transplantation"},{"key":"ref_68","unstructured":"Aronson, J.K. (2016). Meyler\u2019s Side Effects of Drugs, Elsevier."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s41030-025-00289-z","article-title":"A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus","volume":"11","author":"Cheng","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_70","unstructured":"Department of Health and Human Services (2025, September 30). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-oi\/guidelines-adult-adolescent-oi.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/TP.0000000000004855","article-title":"What\u2019s New: Updates on Cytomegalovirus in Solid Organ Transplantation","volume":"108","author":"Stewart","year":"2024","journal-title":"Transplantation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/10600280241237534","article-title":"Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches","volume":"58","author":"Hardinger","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cid\/ciae535","article-title":"Current and Future Strategies for the Prevention and Treatment of Cytomegalovirus Infections in Transplantation","volume":"81","author":"Heldman","year":"2025","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Stobart, C.C., Nosek, J.M., and Moore, M.L. (2017). Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02412"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Mamun, T.I., Ali, A., Hosen, N., Rahman, J., Islam, A., Akib, G., Zaman, K., Rahman, M., Hossain, F.M.A., and Ibenmoussa, S. (2025). Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1364129"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.antiviral.2024.105842","article-title":"The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants","volume":"224","author":"Ianevski","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2023064748","DOI":"10.1542\/peds.2023-064748","article-title":"Safety and Immunogenicity of an mRNA-Based hMPV\/PIV3 Combination Vaccine in Seropositive Children","volume":"153","author":"Essink","year":"2024","journal-title":"Pediatrics"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Principi, N., Fainardi, V., and Esposito, S. (2025). Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment. Viruses, 17.","DOI":"10.3390\/v17081140"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Narsana, N., Ha, D., and Ho, D.Y. (2025). Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?. Viruses, 17.","DOI":"10.3390\/v17050599"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41564-020-0752-7","article-title":"Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase","volume":"5","author":"Cox","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1093\/cid\/ciab113","article-title":"DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study","volume":"73","author":"Chemaly","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/cid\/ciu623","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"59","author":"Chemaly","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults with COVID-19","volume":"80","author":"Mortezavi","year":"2025","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Furuya, C., Yasuda, H., Hiki, M., Shirane, S., Yamana, T., Uchimara, A., Inano, T., Takaku, T., Hamano, Y., and Ando, M. (2024). Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: A report of two cases. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1287300"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Babusis, D., Kim, C., Yang, J., Zhao, X., Geng, G., Ip, C., Kozon, N., Le, H., Leung, J., and Pitts, J. (2025). Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?. Viruses, 17.","DOI":"10.3390\/v17060836"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/fvl-2023-0064","article-title":"Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19","volume":"18","author":"Horga","year":"2023","journal-title":"Future Virol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ewart, G., Bobardt, M., Bentzen, B.H., Yan, Y., Thomson, A., Klumpp, K., Becker, S., Rosenkilde, M.M., Miller, M., and Gallay, P. (2023). Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2. PLoS Pathog., 19.","DOI":"10.1101\/2023.03.29.534854"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1093\/infdis\/jiae471","article-title":"EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus","volume":"231","author":"Levene","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e2576","DOI":"10.1002\/rmv.2576","article-title":"Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e12657","DOI":"10.1111\/tid.12657","article-title":"Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons","volume":"19","author":"Falsey","year":"2017","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.34172\/apb.2023.046","article-title":"Virus-Specific T Cells: Promising Adoptive T Cell Therapy Against Infectious Diseases Following Hematopoietic Stem Cell Transplantation","volume":"13","author":"Jalili","year":"2023","journal-title":"Adv. Pharm. Bull."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:33:00Z","timestamp":1766586780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["v18010008"],"URL":"https:\/\/doi.org\/10.3390\/v18010008","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}